drugset / Trial / NCT04109482
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
NaSingle-groupOpen-labelTreatment
Summary
A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
Timeline
- Start
- 2020-02-17
- Primary completion
- 2023-05-17
- Completion
- 2023-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relmapirazin | Diagnostic / imaging agent | 6e+08 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 24 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |